The endocrine therapies available for the management of breast cancer include selective estrogen-receptor modulators (tamoxifen), a selective estrogen-receptor degrader (fulvestrant) as well as aromatase inhibitors (AIs). This evidence concerns the gene CYP19A1 and breast cancer.